AQST - Aquestive Therapeutics: Specialty Pharma Company With Multiple Value Drivers
Shares of Aquestive Therapeutics (AQST) have lost just over 50% of their value since going public on the Nasdaq in July of 2018 (IPO pricing of $15). So far in 2019 the stock is registering year-to-date gain of 15%.
While the company suffered multiple regulatory setbacks over the past couple quarters, my first thought (after listening to a recent presentation) is that it now appears to be an intriguing turnaround idea with clinical and commercial execution to drive gains for shareholders going forward.
Chart
Figure 1: AQST daily advanced chart (Source: